ClinicalTrials.gg
RecruitingNCT07493395SCLEROCARUpdated Oct 14, 2026

Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy

A Phase 2 interventional study of CD19 CAR T Arm in Scleroderma, Systemic, sponsored by University Hospital, Montpellier. Recruiting at 4 sites in France. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University Hospital, Montpellier · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 14, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Scleroderma, Systemic with a site in France — 44 open to participants now, 48 under way, 7 of them phase 3. Scleroderma, Systemic · France.

Planned enrollment
80th of 81
6 · median 75
Started
2026
with 14 others
Phase 2
21 of 132
9 open now
Primary completion
2028-06
later than 25 of 47 live
Registered
120th of 132
by date
Lead sponsor
5 of 132
University Hospital, Montpellier

Among the 132 studies in Scleroderma, Systemic with a site in France, this one is the 80th largest by planned enrollment of the 81 interventional ones that give a count, is one of 15 that started in 2026, is one of 21 in phase 2, reaches primary completion later than 25 of the 47 other live ones, and was the 120th registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

44 of the 132 studies in Scleroderma, Systemic with a site in France are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Scleroderma, Systemic with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether anti-CD19 CAR T-cell therapy can improve disease activity in adults with severe, treatment-resistant systemic sclerosis (SSc). The study will also assess the safety of this therapy and how CAR T-cells behave in the body.

The main questions are:

Does CAR T-cell therapy reduce skin thickening and other signs of SSc? What side effects occur after receiving CAR T-cells? How do CAR T-cells expand, persist, and affect B-cells and autoantibodies?

Participants will:

Undergo leukapheresis Receive short lymphodepleting chemotherapy Receive one infusion of anti-CD19 CAR T-cells Stay in the hospital for about 10 days Attend follow-up visits for 24 months with clinical exams, blood tests, and organ-function assessments

Optional skin or lymph-node biopsies may be performed in participants who consent to these procedures.

This study aims to provide early evidence on whether CAR T-cell therapy could become a promising treatment option for systemic sclerosis.

Read the detailed description

Systemic sclerosis (SSc) is a rare and severe autoimmune disease characterized by fibrosis of the skin and multiple organs, vasculopathy, and immune dysregulation. Many patients continue to experience active and progressive disease despite conventional immunosuppressive treatments, including disease modifying antirheumatic drugs (DMARDs) and biologics. Therapeutic options remain limited, and there is a significant unmet medical need for innovative approaches targeting the underlying mechanisms of the disease.

Recent preliminary experience from studies conducted in autoimmune diseases-such as lupus, myositis, and systemic sclerosis-suggests that autologous anti CD19 CAR T cell therapy may help reduce disease activity. Reported observations include transient B cell depletion, decreases in autoantibody levels, and improvements in joint, pulmonary, and cardiac manifestations. These early results support further evaluation of CAR T cell therapy in systemic sclerosis in a structured clinical trial setting.

This Phase IIa, multicenter, single-arm study is designed to evaluate the feasibility and safety of autologous anti-CD19 CAR-T cell therapy in adults with active systemic sclerosis who are resistant to immunosuppressive treatments. The study also aims to generate early clinical and biological data to assess the potential value of this therapeutic strategy in this population.

Eligible participants will undergo leukapheresis for T-cell collection. Following standard manufacturing of autologous anti-CD19 CAR-T cells in a GMP (Good Manufacturing Practice)-certified facility, participants will receive a short course of lymphodepleting chemotherapy, followed by a single intravenous infusion of CAR-T cells. They will remain hospitalized for intensive monitoring during the early post-infusion period, in accordance with established procedures for CAR-T cell therapies. Participants with known hypersensitivity to drugs required for treatment-related toxicity are excluded, as specified in the protocol.

After discharge from the hospital, participants will have follow-up visits for up to 24 months. These visits will include clinical and biological assessments as well as appropriate imaging tests to monitor disease activity, treatment safety, and overall health status. Biological samples will also be collected at specific times for centralized analysis.

The study incorporates exploratory immunological and translational research components. These may include monitoring circulating CAR T cells, characterizing immune cell subsets, and evaluating selected biomarkers. Optional skin and lymph node biopsies may be performed in consenting participants to analyze immune cell phenotypes and tissue level changes associated with treatment. Additional exploratory analyses may assess the spatial organization and distribution of immune cells within tissue samples, as described in the study protocol.

Overall, the study aims to provide early data on the use of anti CD19 CAR T cell therapy in systemic sclerosis, including feasibility, safety, and biological signals of activity. The results are expected to contribute to the development of innovative cell based therapeutic strategies for this severe autoimmune disease.

03

Conditions studied

  • Scleroderma, Systemic

Browse trials for

Keywords

  • Systemic Sclerosis
  • Anti-CD19 CAR T-cells
  • Autologous CAR T-cell therapy
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Pre-Inclusion criteria:

  1. Diagnosis of systemic sclerosis according to ACR/EULAR 2013 classification (15).we include in the critera the fulfilling of 2013 EULAR/ACR criteria and specify disease duration (less than 2 years), score/clinical evidence for active disease :
  2. Severe and resistant to low dose and at least 2 treatment including csDMARDs (methotrexate, azathioprine, mycophenolate mofetil) and at least one bDMARDs (Tocilizumab)
  3. Early onset (less than 2 years).
  4. Severity \& progression of disease be defined by :

    1. .mRSS >15 with at least one organ involvement (lung: FVC \<80%, renal involvement, cardiac involvement, Creatinine \< 1.5 mg/dl within 6 months).
    2. mRSS \<15 and lung fibrosis progression (FVC -10% DLCO -15% within 6 months)
  5. patients with active disease (as defined by EUSTAR ≥2.5) and to patients with a worsening disease despite 6 months of at least 2 immunosuppressive treatments including one DMARDs (methotrexate, azathioprine, mycophenolate mofetil), and one biological DMARD rituximab or tocilizumab.
  6. Estimated survival time > 24 weeks
  7. Age: ≥18 ≤64 years old voluntary to participate in the study and sign the
  8. Adequate organ functions assessed :

    1. serum > 40ml/mi
    2. adequate bone marrow function ( ≥9g/dL ; PMN ≥ 1 G/L ; ≥ 100 G/L)
    3. (ALT) ≤ 3 x and total \< 2.0 mg/dL (34 μmol/L) (or \< 3.0 mg/dL [51 μmol/L] for subjects with Gilbert's syndrome)
    4. Adequate respiratory function: no dyspnea or grade I dyspnea ( (NCI CTCAE v 5.0) and oxygen saturation >/= 92% on room air
  9. Highly effective methods

Inclusion criteria

Inclusion criteria:

  1. Adequate organ functions assessed:

    1. serum Creatinine clearance > 40ml/mi
    2. adequate bone marrow function (Hemoglobin ≥9g/dL ; PMN ≥ 1 G/L ; Platelets ≥ 100 G/L)
    3. Alanine aminotransferase (ALT) ≤ 3 x ULN and total bilirubin \< 2.0 mg/dL (34 μmol/L) (or \< 3.0 mg/dL [51 μmol/L] for subjects with Gilbert's syndrome)
    4. Adequate respiratory function: no dyspnea or grade I dyspnea (Common Terminology Criteria for Adverse Events (NCI CTCAE v 5.0) and oxygen saturation >/= 92% on room air
  2. Adequate venous access for apheresis
  3. Leucapheresis : a of 6 weeks for conventional immunosuppressants (i.e. methotrexate, mycophenolate mofetil)
  4. Leucapheresis : at least 12 weeks after biotherapy (i.e. tocilizumab, 6 months for rituximab),

Exclusion criteria

Exclusion Criteria:

  1. Craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia or cerebrovascular hemorrhagic diseases
  2. showing prolonged or history of severe heart diseases or FEVG \< 40%
  3. Lung and / or heart severe dysfunction defined by CVF\<50% and/or DLCO \<40%
  4. Pulmonary arterial hypertension defined by catheterism (mean AP > 25mmHg at rest or > 30mmHg after exercise, PAOP \< 15mmHG)
  5. active, opportunistic, chronic or recurrent infection (including but not limited to: or C virus or ) or covid-19 \< 1 months including active or latent tuberculosis (TB) infection
  6. Contra indication for hematopoietic stem cell transplantation (AHSCT ) or relapsing at least one year after AHSCT
  7. Active hematological or solid neoplasm
  8. Concurrent therapy with systemic (>10 mg/d prednisone equivalent) within 2 weeks prior to inclusion, except inhaled steroids
  9. Methylprednisolone or prednisone (maximum dose 20 mg) instead of agents
  10. T cell targeting drugs (e.g. mycophenolate mofetil, azathioprine, calcineurin inhibitors) within 6 weeks prior to leukapheresis
  11. Previous adoptive T cell therapy or any gene therapy including CAR T cell therapy
  12. within 6 weeks prior to leukapheresis
  13. against any drug or its ingredients/impurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory preparative chemotherapy or rescue medication/salvage therapies for treatment related toxicities
  14. patients without social security coverage;
  15. patients under guardianship;
  16. Male or female patients seeking to conceive a child
  17. Women of unless they are using a highly effective method of starting from the time of enrolment and for at least 12 months following LD chemotherapy and until clearance of CAR-T cells, and sexually active male participants unwilling to use a condom. Female partners of sexually active male participants must be on a highly effective form of birth control from the time of enrolment and for at least 12 months following LD chemotherapy and until clearance of CAR-T cells.
  18. pregnant or breastfeeding women;
  19. patients with advanced cognitive disorders or any other cause preventing their ;
  20. active, clinically significant CNS pathology : If signs or symptoms exist which present diagnostic uncertainty, neurologist consultation will be obtained to confirm the diagnosis of any neurological condition
  21. any comorbidity, whatever it may be, which may, in the opinion of the investigator, place the patient at additional risk or interfere with the monitoring of the study.
  22. Concurrent participation in any other interventional trial and to the lymphodepleting chemotherapy
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    CD19 CAR T Arm

    Participants assigned to this arm will undergo leukapheresis and receive a lymphodepleting chemotherapy regimen, followed by a single intravenous infusion of autologous anti-CD19 CAR T-cells on Day 0. All participants enrolled in the study are included in this single experimental arm

    Biological: CD19 CAR T Arm

Interventions

  • BiologicalCD19 CAR T Arm

    Autologous anti-CD19 CAR-T cells are generated from the participant's leukapheresis product in a Good Manufacturing Practice (GMP)-certified facility using a lentiviral vector. Prior to infusion, participants will receive a short course of lymphodepleting chemotherapy. A single intravenous infusion of autologous anti-CD19 CAR-T cells will be administered on Day 0 at a target dose of 1 × 10⁶ CAR-T cells/kg. Participants will then be monitored in the hospital in accordance with standard post-CAR-T cell infusion procedures.

06

What researchers measure

Primary outcomes

  1. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: 6 Months

Secondary outcomes

  1. Change in European Scleroderma Trial And Research (EUSTAR) activity index

    Clinical response will also be assessed through the European Scleroderma Trial And Research (EUSTAR) disease activity (range 0-10, higher scores indicating greater disease activity) based on a weighted 10-point activity index : Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) \>18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein \>1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted \<70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease

    Time frame: From 3 months to 1 month before CAR-T cell infusion

  2. Change in European Scleroderma Trial And Research (EUSTAR) activity index

    Clinical response will also be assessed through the European Scleroderma Trial And Research (EUSTAR) disease activity (range 0-10, higher scores indicating greater disease activity) based on a weighted 10-point activity index : Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) \>18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein \>1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted \<70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease

    Time frame: 1 month before CAR-T cell infusion

  3. Change in European Scleroderma Trial And Research (EUSTAR) activity index

    Clinical response will also be assessed through the European Scleroderma Trial And Research (EUSTAR) disease activity (range 0-10, higher scores indicating greater disease activity) based on a weighted 10-point activity index : Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) \>18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein \>1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted \<70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease

    Time frame: Day 0 (CAR-T cell infusion)

  4. Change in European Scleroderma Trial And Research (EUSTAR) activity index

    Clinical response will also be assessed through the European Scleroderma Trial And Research (EUSTAR) disease activity (range 0-10, higher scores indicating greater disease activity) based on a weighted 10-point activity index : Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) \>18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein \>1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted \<70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease

    Time frame: Day 28 after CAR-T cell infusion

  5. Change in European Scleroderma Trial And Research (EUSTAR) activity index

    Clinical response will also be assessed through the European Scleroderma Trial And Research (EUSTAR) disease activity (range 0-10, higher scores indicating greater disease activity) based on a weighted 10-point activity index : Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) \>18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein \>1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted \<70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease

    Time frame: 3 Months

  6. Change in European Scleroderma Trial And Research (EUSTAR) activity index

    Clinical response will also be assessed through the European Scleroderma Trial And Research (EUSTAR) disease activity (range 0-10, higher scores indicating greater disease activity) based on a weighted 10-point activity index : Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) \>18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein \>1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted \<70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease

    Time frame: 6 Months

  7. Change in European Scleroderma Trial And Research (EUSTAR) activity index

    Clinical response will also be assessed through the European Scleroderma Trial And Research (EUSTAR) disease activity (range 0-10, higher scores indicating greater disease activity) based on a weighted 10-point activity index : Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) \>18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein \>1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted \<70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease

    Time frame: 12 Months

  8. Change in European Scleroderma Trial And Research (EUSTAR) activity index

    Clinical response will also be assessed through the European Scleroderma Trial And Research (EUSTAR) disease activity (range 0-10, higher scores indicating greater disease activity) based on a weighted 10-point activity index : Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) \>18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein \>1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted \<70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease

    Time frame: 24 Months

  9. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: From 3 months to 1 month before CAR-T infusion

  10. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: 1 month before CAR-T infusion

  11. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: Day 0 (CAR-T infusion)

  12. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: Day 28 after infusion

  13. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: 2 Months

  14. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: 3 Months

  15. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: 6 Months

  16. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: 12 months

  17. modified Rodnan skin score (mRSS)

    Clinical response will be assessed through the modified Rodnan skin score (mRSS) which measures skin thickness on a scale of 0 to 3 at 17 anatomical sites (score range 0-51, higher scores indicating worse skin fibrosis)

    Time frame: 24 months

  18. Change in Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS)

    Clinical response will be assessed using the revised Combined Response Index in diffuse cutaneous Systemic Sclerosis (rCRISS). The rCRISS is a 2-step composite score: Step 1: Patients are considered not improved if any of the following occur: scleroderma renal crisis, significant FVC decline (≥15% or FVC% \<80%), new left ventricular failure (LVEF ≤45%), new pulmonary arterial hypertension requiring treatment, gastrointestinal dysmotility requiring nutritional support, or digital ischemia requiring treatment or hospitalization. Step 2: For other patients, improvement is defined as ≥40% improvement in at least 3 of 5 measures: mRSS, HAQ-DI, patient global assessment, clinician global assessment, and percent predicted FVC. Additional assessments include spirometry (FVC, DLCO), thoracic CT fibrosis, echocardiography (LVEF, global longitudinal strain), cardiac MRI, and SHAQ score

    Time frame: From 3 months to 1 month before CAR-T infusion

  19. Change in Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS)

    Clinical response will be assessed using the revised Combined Response Index in diffuse cutaneous Systemic Sclerosis (rCRISS). The rCRISS is a 2-step composite score: Step 1: Patients are considered not improved if any of the following occur: scleroderma renal crisis, significant FVC decline (≥15% or FVC% \<80%), new left ventricular failure (LVEF ≤45%), new pulmonary arterial hypertension requiring treatment, gastrointestinal dysmotility requiring nutritional support, or digital ischemia requiring treatment or hospitalization. Step 2: For other patients, improvement is defined as ≥40% improvement in at least 3 of 5 measures: mRSS, HAQ-DI, patient global assessment, clinician global assessment, and percent predicted FVC. Additional assessments include spirometry (FVC, DLCO), thoracic CT fibrosis, echocardiography (LVEF, global longitudinal strain), cardiac MRI, and SHAQ score

    Time frame: 1 month before CAR-T infusion

  20. Change in Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS)

    Clinical response will be assessed using the revised Combined Response Index in diffuse cutaneous Systemic Sclerosis (rCRISS). The rCRISS is a 2-step composite score: Step 1: Patients are considered not improved if any of the following occur: scleroderma renal crisis, significant FVC decline (≥15% or FVC% \<80%), new left ventricular failure (LVEF ≤45%), new pulmonary arterial hypertension requiring treatment, gastrointestinal dysmotility requiring nutritional support, or digital ischemia requiring treatment or hospitalization. Step 2: For other patients, improvement is defined as ≥40% improvement in at least 3 of 5 measures: mRSS, HAQ-DI, patient global assessment, clinician global assessment, and percent predicted FVC. Additional assessments include spirometry (FVC, DLCO), thoracic CT fibrosis, echocardiography (LVEF, global longitudinal strain), cardiac MRI, and SHAQ score

    Time frame: Day 0 (CAR-T infusion)

  21. Change in Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS)

    Clinical response will be assessed using the revised Combined Response Index in diffuse cutaneous Systemic Sclerosis (rCRISS). The rCRISS is a 2-step composite score: Step 1: Patients are considered not improved if any of the following occur: scleroderma renal crisis, significant FVC decline (≥15% or FVC% \<80%), new left ventricular failure (LVEF ≤45%), new pulmonary arterial hypertension requiring treatment, gastrointestinal dysmotility requiring nutritional support, or digital ischemia requiring treatment or hospitalization. Step 2: For other patients, improvement is defined as ≥40% improvement in at least 3 of 5 measures: mRSS, HAQ-DI, patient global assessment, clinician global assessment, and percent predicted FVC. Additional assessments include spirometry (FVC, DLCO), thoracic CT fibrosis, echocardiography (LVEF, global longitudinal strain), cardiac MRI, and SHAQ score

    Time frame: Day 28 after infusion

  22. Change in Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS)

    Clinical response will be assessed using the revised Combined Response Index in diffuse cutaneous Systemic Sclerosis (rCRISS). The rCRISS is a 2-step composite score: Step 1: Patients are considered not improved if any of the following occur: scleroderma renal crisis, significant FVC decline (≥15% or FVC% \<80%), new left ventricular failure (LVEF ≤45%), new pulmonary arterial hypertension requiring treatment, gastrointestinal dysmotility requiring nutritional support, or digital ischemia requiring treatment or hospitalization. Step 2: For other patients, improvement is defined as ≥40% improvement in at least 3 of 5 measures: mRSS, HAQ-DI, patient global assessment, clinician global assessment, and percent predicted FVC. Additional assessments include spirometry (FVC, DLCO), thoracic CT fibrosis, echocardiography (LVEF, global longitudinal strain), cardiac MRI, and SHAQ score

    Time frame: 2 Months

  23. Change in Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS)

    Clinical response will be assessed using the revised Combined Response Index in diffuse cutaneous Systemic Sclerosis (rCRISS). The rCRISS is a 2-step composite score: Step 1: Patients are considered not improved if any of the following occur: scleroderma renal crisis, significant FVC decline (≥15% or FVC% \<80%), new left ventricular failure (LVEF ≤45%), new pulmonary arterial hypertension requiring treatment, gastrointestinal dysmotility requiring nutritional support, or digital ischemia requiring treatment or hospitalization. Step 2: For other patients, improvement is defined as ≥40% improvement in at least 3 of 5 measures: mRSS, HAQ-DI, patient global assessment, clinician global assessment, and percent predicted FVC. Additional assessments include spirometry (FVC, DLCO), thoracic CT fibrosis, echocardiography (LVEF, global longitudinal strain), cardiac MRI, and SHAQ score

    Time frame: 3 Months

  24. Change in Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS)

    Clinical response will be assessed using the revised Combined Response Index in diffuse cutaneous Systemic Sclerosis (rCRISS). The rCRISS is a 2-step composite score: Step 1: Patients are considered not improved if any of the following occur: scleroderma renal crisis, significant FVC decline (≥15% or FVC% \<80%), new left ventricular failure (LVEF ≤45%), new pulmonary arterial hypertension requiring treatment, gastrointestinal dysmotility requiring nutritional support, or digital ischemia requiring treatment or hospitalization. Step 2: For other patients, improvement is defined as ≥40% improvement in at least 3 of 5 measures: mRSS, HAQ-DI, patient global assessment, clinician global assessment, and percent predicted FVC. Additional assessments include spirometry (FVC, DLCO), thoracic CT fibrosis, echocardiography (LVEF, global longitudinal strain), cardiac MRI, and SHAQ score

    Time frame: 6 Months

  25. Change in Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS)

    Clinical response will be assessed using the revised Combined Response Index in diffuse cutaneous Systemic Sclerosis (rCRISS). The rCRISS is a 2-step composite score: Step 1: Patients are considered not improved if any of the following occur: scleroderma renal crisis, significant FVC decline (≥15% or FVC% \<80%), new left ventricular failure (LVEF ≤45%), new pulmonary arterial hypertension requiring treatment, gastrointestinal dysmotility requiring nutritional support, or digital ischemia requiring treatment or hospitalization. Step 2: For other patients, improvement is defined as ≥40% improvement in at least 3 of 5 measures: mRSS, HAQ-DI, patient global assessment, clinician global assessment, and percent predicted FVC. Additional assessments include spirometry (FVC, DLCO), thoracic CT fibrosis, echocardiography (LVEF, global longitudinal strain), cardiac MRI, and SHAQ score

    Time frame: 12 Months

  26. Change in Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS)

    Clinical response will be assessed using the revised Combined Response Index in diffuse cutaneous Systemic Sclerosis (rCRISS). The rCRISS is a 2-step composite score: Step 1: Patients are considered not improved if any of the following occur: scleroderma renal crisis, significant FVC decline (≥15% or FVC% \<80%), new left ventricular failure (LVEF ≤45%), new pulmonary arterial hypertension requiring treatment, gastrointestinal dysmotility requiring nutritional support, or digital ischemia requiring treatment or hospitalization. Step 2: For other patients, improvement is defined as ≥40% improvement in at least 3 of 5 measures: mRSS, HAQ-DI, patient global assessment, clinician global assessment, and percent predicted FVC. Additional assessments include spirometry (FVC, DLCO), thoracic CT fibrosis, echocardiography (LVEF, global longitudinal strain), cardiac MRI, and SHAQ score

    Time frame: 24 Months

  27. Change in the lung capacity FVC (forced vital capacity)

    To assess the impact of the treatment on pulmonary function, FVC will be assessed during functionnal exploration test lab and we will evaluate the improvement in FVC over time

    Time frame: From 3 months to 1 month before CAR-T infusion

  28. Change in the lung capacity FVC (forced vital capacity)

    To assess the impact of the treatment on pulmonary function, FVC will be assessed during functionnal exploration test lab and we will evaluate the improvement in FVC over time

    Time frame: 1 month before CAR-T infusion

  29. Change in the lung capacity FVC (forced vital capacity)

    To assess the impact of the treatment on pulmonary function, FVC will be assessed during functionnal exploration test lab and we will evaluate the improvement in FVC over time

    Time frame: 3 Months

  30. Change in the lung capacity FVC (forced vital capacity)

    To assess the impact of the treatment on pulmonary function, FVC will be assessed during functionnal exploration test lab and we will evaluate the improvement in FVC over time

    Time frame: 6 Months

  31. Change in the lung capacity FVC (forced vital capacity)

    To assess the impact of the treatment on pulmonary function, FVC will be assessed during functionnal exploration test lab and we will evaluate the improvement in FVC over time

    Time frame: 12 Months

  32. Change in the lung capacity FVC (forced vital capacity)

    To assess the impact of the treatment on pulmonary function, FVC will be assessed during functionnal exploration test lab and we will evaluate the improvement in FVC over time

    Time frame: 24 Months

  33. Change in DLCO (diffusing capacity of the lung for carbon monoxide)

    The efficacy of the treatment on pulmonary function will also be analyzed by monitoring changes in DLCO (diffusing capacity of the lung for carbon monoxide), quantifiy during functionnal exploration test lab

    Time frame: From 3 months to 1 month before CAR-T infusion

  34. Change in DLCO (diffusing capacity of the lung for carbon monoxide)

    The efficacy of the treatment on pulmonary function will also be analyzed by monitoring changes in DLCO (diffusing capacity of the lung for carbon monoxide), quantifiy during functionnal exploration test lab

    Time frame: 1 month before CAR-T infusion

  35. Change in DLCO (diffusing capacity of the lung for carbon monoxide)

    The efficacy of the treatment on pulmonary function will also be analyzed by monitoring changes in DLCO (diffusing capacity of the lung for carbon monoxide), quantifiy during functionnal exploration test lab

    Time frame: 3 Months

  36. Change in DLCO (diffusing capacity of the lung for carbon monoxide)

    The efficacy of the treatment on pulmonary function will also be analyzed by monitoring changes in DLCO (diffusing capacity of the lung for carbon monoxide), quantifiy during functionnal exploration test lab

    Time frame: 6 Months

  37. Change in DLCO (diffusing capacity of the lung for carbon monoxide)

    The efficacy of the treatment on pulmonary function will also be analyzed by monitoring changes in DLCO (diffusing capacity of the lung for carbon monoxide), quantifiy during functionnal exploration test lab

    Time frame: 12 Months

  38. Change in DLCO (diffusing capacity of the lung for carbon monoxide)

    The efficacy of the treatment on pulmonary function will also be analyzed by monitoring changes in DLCO (diffusing capacity of the lung for carbon monoxide), quantifiy during functionnal exploration test lab

    Time frame: 24 Months

  39. Extent of fibrosis on pulmonary CT (Computed Tomography)

    Pulmonary response will be also assessment by CT scan and expressed as percentage of parenchyma affected. The type of parenchymal involvement willbe specified (ground glass, honeycomb)

    Time frame: From 3 months to 1 month before CAR-T infusion

  40. Extent of fibrosis on pulmonary CT(Computed Tomography)

    Pulmonary response will be also assessment by CT scan and expressed as percentage of parenchyma affected. The type of parenchymal involvement willbe specified (ground glass, honeycomb)

    Time frame: 3 Months

  41. Extent of fibrosis on pulmonary CT(Computed Tomography)

    Pulmonary response will be also assessment by CT scan and expressed as percentage of parenchyma affected. The type of parenchymal involvement willbe specified (ground glass, honeycomb)

    Time frame: 12 Months

  42. Extent of fibrosis on pulmonary CT(Computed Tomography)

    Pulmonary response will be also assessment by CT scan and expressed as percentage of parenchyma affected. The type of parenchymal involvement willbe specified (ground glass, honeycomb)

    Time frame: 24 Months

  43. Change in cardiac ejection fraction and global longitudinal strain

    A transthoracic cardiac ultrasound will be performed regularly to assess the effect of treatment on the left ventricular ejection fraction, as well as the global longitudinal strain (GLS).

    Time frame: From 3 months to 1 month before CAR-T infusion

  44. Change in cardiac ejection fraction and global longitudinal strain

    A transthoracic cardiac ultrasound will be performed regularly to assess the effect of treatment on the left ventricular ejection fraction, as well as the global longitudinal strain (GLS).

    Time frame: 3 Months

  45. Change in cardiac ejection fraction and global longitudinal strain

    A transthoracic cardiac ultrasound will be performed regularly to assess the effect of treatment on the left ventricular ejection fraction, as well as the global longitudinal strain (GLS).

    Time frame: 12 Months

  46. Change in cardiac ejection fraction and global longitudinal strain

    A transthoracic cardiac ultrasound will be performed regularly to assess the effect of treatment on the left ventricular ejection fraction, as well as the global longitudinal strain (GLS).

    Time frame: 24 Months

  47. Cardiomyopathy, change in cardiac MRI (Magnetic Resonance Imaging) signal

    A cardiac MRI (Magnetic Resonance Imaging) will be performed at baseline and at follow-up visit to evaluate the effect of treatment on T1 and T2 mapping, late gadolinium enhancement (LGE), extracellular volume ( ECV) mapping and indirect indicators of pulmonary hypertension

    Time frame: From 3 months to 1 month before CAR-T infusion

  48. Cardiomyopathy, change in cardiac MRI (Magnetic Resonance Imaging) signal

    A cardiac MRI (Magnetic Resonance Imaging) will be performed at baseline and at follow-up visit to evaluate the effect of treatment on T1 and T2 mapping, late gadolinium enhancement (LGE), extracellular volume ( ECV) mapping and indirect indicators of pulmonary hypertension

    Time frame: 12 Months

  49. Cardiomyopathy, change in cardiac MRI (Magnetic Resonance Imaging) signal

    A cardiac MRI (Magnetic Resonance Imaging) will be performed at baseline and at follow-up visit to evaluate the effect of treatment on T1 and T2 mapping, late gadolinium enhancement (LGE), extracellular volume ( ECV) mapping and indirect indicators of pulmonary hypertension

    Time frame: 24 Months

  50. Change in scleroderma-adapted Scleroderma Health Assessment Questionnaire (SHAQ) score

    Clinical response will be assessed using SHAQ : the patient will complete a self-assessment questionnaire on their health status during systemic sclerosis (SSc) and we will compare the scores at each stage

    Time frame: Day 0 (CAR-T infusion)

  51. Change in scleroderma-adapted Scleroderma Health Assessment Questionnaire (SHAQ) score

    Clinical response will be assessed using SHAQ : the patient will complete a self-assessment questionnaire on their health status during systemic sclerosis (SSc) and we will compare the scores at each stage

    Time frame: Day 28 after CAR-T cell infusion

  52. Change in scleroderma-adapted Scleroderma Health Assessment Questionnaire (SHAQ) score

    Clinical response will be assessed using SHAQ : the patient will complete a self-assessment questionnaire on their health status during systemic sclerosis (SSc) and we will compare the scores at each stage

    Time frame: 3 Months

  53. Change in scleroderma-adapted Scleroderma Health Assessment Questionnaire (SHAQ) score

    Clinical response will be assessed using SHAQ : the patient will complete a self-assessment questionnaire on their health status during systemic sclerosis (SSc) and we will compare the scores at each stage

    Time frame: 6 Months

  54. Change in scleroderma-adapted Scleroderma Health Assessment Questionnaire (SHAQ) score

    Clinical response will be assessed using SHAQ : the patient will complete a self-assessment questionnaire on their health status during systemic sclerosis (SSc) and we will compare the scores at each stage

    Time frame: 12 Months

  55. Change in scleroderma-adapted Scleroderma Health Assessment Questionnaire (SHAQ) score

    Clinical response will be assessed using SHAQ : the patient will complete a self-assessment questionnaire on their health status during systemic sclerosis (SSc) and we will compare the scores at each stage

    Time frame: 24 Months

  56. Change in Health Assessment Questionnaire Disability Index HAQ-DI score

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a quantitative tool used to measure health related quality of life assessments related to SSc ; Clinical response will be assessed using HAQ-DI and we will compare the scores at each stage

    Time frame: Day 0 (CAR-T cell infusion)

  57. Change in Health Assessment Questionnaire Disability Index HAQ-DI score

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a quantitative tool used to measure health related quality of life assessments related to SSc ; Clinical response will be assessed using HAQ-DI and we will compare the scores at each stage

    Time frame: Day 28 after CAR-T cell infusion

  58. Change in Health Assessment Questionnaire Disability Index HAQ-DI score

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a quantitative tool used to measure health related quality of life assessments related to SSc ; Clinical response will be assessed using HAQ-DI and we will compare the scores at each stage

    Time frame: 3 Months

  59. Change in Health Assessment Questionnaire Disability Index HAQ-DI score

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a quantitative tool used to measure health related quality of life assessments related to SSc ; Clinical response will be assessed using HAQ-DI and we will compare the scores at each stage

    Time frame: 6 Months

  60. Change in Health Assessment Questionnaire Disability Index HAQ-DI score

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a quantitative tool used to measure health related quality of life assessments related to SSc ; Clinical response will be assessed using HAQ-DI and we will compare the scores at each stage

    Time frame: 12 Months

  61. Change in Health Assessment Questionnaire Disability Index HAQ-DI score

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a quantitative tool used to measure health related quality of life assessments related to SSc ; Clinical response will be assessed using HAQ-DI and we will compare the scores at each stage

    Time frame: 24 Months

  62. Change in Health Assessment Questionnaire Cochin Hand score

    Clinical response will also be assessed using the Cochin Hand Function Scale, a validated tool that quantifies disability resulting from hand functional impairment.

    Time frame: Day 0 (CAR-T cell infusion)

  63. Change in Health Assessment Questionnaire Cochin Hand score

    Clinical response will also be assessed using the Cochin Hand Function Scale, a validated tool that quantifies disability resulting from hand functional impairment.

    Time frame: Day 28 after CAR-T cell infusion

  64. Change in Health Assessment Questionnaire Cochin Hand score

    Clinical response will also be assessed using the Cochin Hand Function Scale, a validated tool that quantifies disability resulting from hand functional impairment.

    Time frame: 3 Months

  65. Change in Health Assessment Questionnaire Cochin Hand score

    Clinical response will also be assessed using the Cochin Hand Function Scale, a validated tool that quantifies disability resulting from hand functional impairment.

    Time frame: 6 Months

  66. Change in Health Assessment Questionnaire Cochin Hand score

    Clinical response will also be assessed using the Cochin Hand Function Scale, a validated tool that quantifies disability resulting from hand functional impairment.

    Time frame: 12 Months

  67. Change in Health Assessment Questionnaire Cochin Hand score

    Clinical response will also be assessed using the Cochin Hand Function Scale, a validated tool that quantifies disability resulting from hand functional impairment.

    Time frame: 24 Months

  68. Change in quality of life Questionnaire SF-36

    Clinical response will also be assessed using the SF36 score collected at each time point through the SF36 self-assessment questionnaire, which evaluates the patient's quality of life across eight domains, including physical functioning, role limitations, bodily pain, general health, vitality, social functioning, emotional well-being, and mental health

    Time frame: Day 0 (CAR-T cell infusion)

  69. Change in quality of life Questionnaire SF-36

    Clinical response will also be assessed using the SF36 score collected at each time point through the 36-Item Short Form Survey (SF-36) self-assessment questionnaire, which evaluates the patient's quality of life across eight domains, including physical functioning, role limitations, bodily pain, general health, vitality, social functioning, emotional well-being, and mental health

    Time frame: Day 28 after CAR-T cell infusion

  70. Change in quality of life Questionnaire SF-36

    Clinical response will also be assessed using the SF36 score collected at each time point through the 36-Item Short Form Survey (SF-36) self-assessment questionnaire, which evaluates the patient's quality of life across eight domains, including physical functioning, role limitations, bodily pain, general health, vitality, social functioning, emotional well-being, and mental health

    Time frame: 3 Months

  71. Change in quality of life Questionnaire SF-36

    Clinical response will also be assessed using the SF36 score collected at each time point through the 36-Item Short Form Survey (SF-36) self-assessment questionnaire, which evaluates the patient's quality of life across eight domains, including physical functioning, role limitations, bodily pain, general health, vitality, social functioning, emotional well-being, and mental health

    Time frame: 6 Months

  72. Change in quality of life Questionnaire SF-36

    Clinical response will also be assessed using the SF36 score collected at each time point through the 36-Item Short Form Survey (SF-36) self-assessment questionnaire, which evaluates the patient's quality of life across eight domains, including physical functioning, role limitations, bodily pain, general health, vitality, social functioning, emotional well-being, and mental health

    Time frame: 12 Months

  73. Change in quality of life Questionnaire SF-36

    Clinical response will also be assessed using the SF36 score collected at each time point through the 36-Item Short Form Survey (SF-36) self-assessment questionnaire, which evaluates the patient's quality of life across eight domains, including physical functioning, role limitations, bodily pain, general health, vitality, social functioning, emotional well-being, and mental health

    Time frame: 24 Months

  74. Change in the university of California Los Angeles scleroderma clinical trials consortium gastrointestinal tract (ULCA-SCTC GIT) score

    to evaluate disease response on to systemic sclerosis associated gastrointestinal tract symptoms severity and its impact on patients' well-being, we will compare ULCA-SCTC GIT Score, which is a self-administered questionnaire completed at each time point

    Time frame: Day 0 (CAR-T cell infusion)

  75. Change in the university of California Los Angeles scleroderma clinical trials consortium gastrointestinal tract (ULCA-SCTC GIT) score

    to evaluate disease response on to systemic sclerosis associated gastrointestinal tract symptoms severity and its impact on patients' well-being, we will compare ULCA-SCTC GIT Score, which is a self-administered questionnaire completed at each time point

    Time frame: Day 28 after CAR-T cell infusion

  76. Change in the university of California Los Angeles scleroderma clinical trials consortium gastrointestinal tract (ULCA-SCTC GIT) score

    to evaluate disease response on to systemic sclerosis associated gastrointestinal tract symptoms severity and its impact on patients' well-being, we will compare ULCA-SCTC GIT Score, which is a self-administered questionnaire completed at each time point

    Time frame: 3 Months

  77. Change in the university of California Los Angeles scleroderma clinical trials consortium gastrointestinal tract (ULCA-SCTC GIT) score

    to evaluate disease response on to systemic sclerosis associated gastrointestinal tract symptoms severity and its impact on patients' well-being, we will compare ULCA-SCTC GIT Score, which is a self-administered questionnaire completed at each time point

    Time frame: 6 Months

  78. Change in the university of California Los Angeles scleroderma clinical trials consortium gastrointestinal tract (ULCA-SCTC GIT) score

    to evaluate disease response on to systemic sclerosis associated gastrointestinal tract symptoms severity and its impact on patients' well-being, we will compare ULCA-SCTC GIT Score, which is a self-administered questionnaire completed at each time point

    Time frame: 12 Months

  79. Change in the university of California Los Angeles scleroderma clinical trials consortium gastrointestinal tract (ULCA-SCTC GIT) score

    to evaluate disease response on to systemic sclerosis associated gastrointestinal tract symptoms severity and its impact on patients' well-being, we will compare ULCA-SCTC GIT Score, which is a self-administered questionnaire completed at each time point

    Time frame: 24 Months

  80. Change in Malnutrition Universal Screening Tool (MUST) score

    We will also assess the effect of treatment on digestive impairment in scleroderma patient, as well as their risk of malnutrition, using the MUST score. This evaluation includes measuring the percentage of weight loss over the previous 3 to 6 months, calculating body mass index, and determining whether the patient has been seriously ill and experienced a period of more than 5 days without nutritional intake

    Time frame: From 3 months to 1 month before CAR-T cell infusion

  81. Change in Malnutrition Universal Screening Tool (MUST) score

    We will also assess the effect of treatment on digestive impairment in scleroderma patient, as well as their risk of malnutrition, using the MUST score. This evaluation includes measuring the percentage of weight loss over the previous 3 to 6 months, calculating body mass index, and determining whether the patient has been seriously ill and experienced a period of more than 5 days without nutritional intake

    Time frame: 1 month before CAR-T cell infusion

  82. Change in Malnutrition Universal Screening Tool (MUST) score

    We will also assess the effect of treatment on digestive impairment in scleroderma patient, as well as their risk of malnutrition, using the MUST score. This evaluation includes measuring the percentage of weight loss over the previous 3 to 6 months, calculating body mass index, and determining whether the patient has been seriously ill and experienced a period of more than 5 days without nutritional intake

    Time frame: Day 0 (CAR-T cell infusion)

  83. Change in Malnutrition Universal Screening Tool (MUST) score

    We will also assess the effect of treatment on digestive impairment in scleroderma patient, as well as their risk of malnutrition, using the MUST score. This evaluation includes measuring the percentage of weight loss over the previous 3 to 6 months, calculating body mass index, and determining whether the patient has been seriously ill and experienced a period of more than 5 days without nutritional intake

    Time frame: Day 28 after CAR-T cell infusion

  84. Change in Malnutrition Universal Screening Tool (MUST) score

    We will also assess the effect of treatment on digestive impairment in scleroderma patient, as well as their risk of malnutrition, using the MUST score. This evaluation includes measuring the percentage of weight loss over the previous 3 to 6 months, calculating body mass index, and determining whether the patient has been seriously ill and experienced a period of more than 5 days without nutritional intake

    Time frame: 3 Months

  85. Change in Malnutrition Universal Screening Tool (MUST) score

    We will also assess the effect of treatment on digestive impairment in scleroderma patient, as well as their risk of malnutrition, using the MUST score. This evaluation includes measuring the percentage of weight loss over the previous 3 to 6 months, calculating body mass index, and determining whether the patient has been seriously ill and experienced a period of more than 5 days without nutritional intake

    Time frame: 6 Months

  86. Change in Malnutrition Universal Screening Tool (MUST) score

    We will also assess the effect of treatment on digestive impairment in scleroderma patient, as well as their risk of malnutrition, using the MUST score. This evaluation includes measuring the percentage of weight loss over the previous 3 to 6 months, calculating body mass index, and determining whether the patient has been seriously ill and experienced a period of more than 5 days without nutritional intake

    Time frame: 12 Months

  87. Change in Malnutrition Universal Screening Tool (MUST) score

    We will also assess the effect of treatment on digestive impairment in scleroderma patient, as well as their risk of malnutrition, using the MUST score. This evaluation includes measuring the percentage of weight loss over the previous 3 to 6 months, calculating body mass index, and determining whether the patient has been seriously ill and experienced a period of more than 5 days without nutritional intake

    Time frame: 24 Months

  88. Anti-antibody titers

    Measurement of antinuclear antibodies (ANA), anti-centromere, anti-DNA, anti-Topoisomerase, and TRAK antibody titers following CAR T anti-CD19 cell administration

    Time frame: From 3 months to 1 month before CAR-T cell infusion

  89. Anti-antibody titers

    Measurement of antinuclear antibodies (ANA), anti-centromere, anti-DNA, anti-Topoisomerase, and TRAK antibody titers following CAR T anti-CD19 cell administration

    Time frame: Day 28 after CAR-T cell infusion

  90. Anti-antibody titers

    Measurement of antinuclear antibodies (ANA), anti-centromere, anti-DNA, anti-Topoisomerase, and TRAK antibody titers following CAR T anti-CD19 cell administration

    Time frame: 6 Months

  91. Anti-antibody titers

    Measurement of antinuclear antibodies (ANA), anti-centromere, anti-DNA, anti-Topoisomerase, and TRAK antibody titers following CAR T anti-CD19 cell administration

    Time frame: 12 Months

  92. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: Day 0 (CAR-T cell infusion)

  93. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: Day 4 after CAR-T cell infusion

  94. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: Day 7 after CAR-T cell infusion

  95. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: Day 10 after CAR-T cell infusion

  96. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: Day 14 after CAR-T cell infusion

  97. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: Day 21 after CAR-T cell infusion

  98. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: Day 28 after CAR-T cell infusion

  99. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: 3 Months

  100. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: 6 Months

  101. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: 12 Months

  102. CAR T cell counts

    Quantification of CAR T cells using flow cytometry and qPCR to assess expansion and persistence after CAR T anti-CD19 infusion

    Time frame: 24 Months

  103. Immunophenotyping of B, T, and NK cells subsets

    Immunophenotyping of B cells, T cells, NK cells, and immune subpopulations to evaluate immune reconstitution following CAR T infusion

    Time frame: Day -14 (14 days before CAR-T infusion)

  104. Immunophenotyping of B, T, and NK cells subsets

    Immunophenotyping of B cells, T cells, NK cells, and immune subpopulations to evaluate immune reconstitution following CAR T infusion

    Time frame: Day 28 after CAR-T cell infusion

  105. Immunophenotyping of B, T, and NK cells subsets

    Immunophenotyping of B cells, T cells, NK cells, and immune subpopulations to evaluate immune reconstitution following CAR T infusion

    Time frame: 3 Months

  106. Immunophenotyping of B, T, and NK cells subsets

    Immunophenotyping of B cells, T cells, NK cells, and immune subpopulations to evaluate immune reconstitution following CAR T infusion

    Time frame: 6 Months

  107. Immunophenotyping of B, T, and NK cells subsets

    Immunophenotyping of B cells, T cells, NK cells, and immune subpopulations to evaluate immune reconstitution following CAR T infusion

    Time frame: 12 Months

  108. B-cell receptor (BCR) repertoire analysis

    BCR repertoire analysis performed on B cells from Systemic Sclerosis (SSc) patients. Assessment occurs at Month 6 if B-cell percentage is \>50% of baseline; otherwise at Month 12 after CAR T anti-CD19 administration

    Time frame: Day -14 (14 days before CAR-T infusion)

  109. B-cell receptor (BCR) repertoire analysis

    BCR repertoire analysis performed on B cells from Systemic Sclerosis (SSc) patients. Assessment occurs at Month 6 if B-cell percentage is \>50% of baseline; otherwise at Month 12 after CAR T anti-CD19 administration

    Time frame: 6 Months

  110. B-cell receptor (BCR) repertoire analysis

    BCR repertoire analysis performed on B cells from Systemic Sclerosis (SSc) patients. Assessment occurs at Month 6 if B-cell percentage is \>50% of baseline; otherwise at Month 12 after CAR T anti-CD19 administration

    Time frame: 12 Months

  111. B-cell receptor (BCR) repertoire analysis

    BCR repertoire analysis performed on B cells from Systemic Sclerosis (SSc) patients. Assessment occurs at Month 6 if B-cell percentage is \>50% of baseline; otherwise at Month 12 after CAR T anti-CD19 administration

    Time frame: 24 Months

  112. Skin biopsies for single-cell phenotyping

    Skin biopsies (for patients who have given their consent) performed at baseline for single-cell phenotyping analyses.

    Time frame: From 3 months to 1 month before CAR-T infusion

  113. Skin biopsies for single-cell phenotyping

    Skin biopsies (for patients who have given their consent) performed at M3 for single-cell phenotyping analyses.

    Time frame: 3 Months

  114. lymph node biopsies for single-cell phenotyping

    lymph node biopsies (for patients who have given their consent) performed at Month 3 for single-cell phenotyping analyses.

    Time frame: 3 Months

  115. Incidence rate of adverse events

    Incidence rate of adverse events graded according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 and classified following the American Society of Clinical Oncology (ASCO) guidelines

    Time frame: Day -14 to 24 months

  116. Incidence of Cytokine Release Syndrome (CRS)

    Incidence and severity of Cytokine Release Syndrome (CRS), graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading system.

    Time frame: Day -14 to 24 months

  117. Incidence of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

    Incidence and severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading system

    Time frame: Day -14 to 24 months

  118. Incidence of Cytopenias

    Incidence and severity of cytopenias, graded according to the consensus grading system of the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) consensus grading system

    Time frame: Day -14 to 24 months

  119. Incidence of Infections

    Incidence and severity of infections, graded according to Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Time frame: Day -14 to 24 months

  120. Incidence of Cardiac Events

    Incidence and severity of cardiac adverse events, graded according to Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Time frame: Day -14 to 24 months

  121. Incidence of Acute Kidney Injury

    Incidence and severity of acute kidney injury, graded according to Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Time frame: Day -14 to 24 months

  122. Incidence of Scleroderma Renal Crisis

    Incidence of clinically diagnosed scleroderma renal crisis

    Time frame: Day -14 to 24 months

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 25, 2026
StartActual
Jun 11, 2026
Primary completionEst.
Jun 11, 2028
CompletionEst.
Jun 11, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 14, 2026
Sites
4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
Show 4 sites
  • CHRU Lille · Lille, Franceno status→Not yet recruiting
  • Montpellier University Hospital · Montpellier, Franceno status→Recruiting
  • APHP Necker · Paris, Franceno status→Not yet recruiting
  • Chu Rouen · Rouen, Franceno status→Not yet recruiting
Oct 14, 2026
Contact
Study contact now listed: added c•••@chu-montpellier.fr · •••4853. See the current contact
Oct 14, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • CHRU Lille · Lille, FranceContact added d•••@chu-lille.frContact added (no phone or email listed)
  • Montpellier University Hospital · Montpellier, FranceContact added (no phone or email listed)Contact added c•••@inserm.fr · •••4853
  • APHP Necker · Paris, FranceContact added y•••@me.comContact added (no phone or email listed)
  • Chu Rouen · Rouen, FranceContact added o•••@chu-rouen.fr
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Active, not recruiting→Recruiting
    4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
    Show 4 sites
    • CHRU Lille · Lille, Franceno status→Not yet recruiting
    • Montpellier University Hospital · Montpellier, Franceno status→Recruiting
    • APHP Necker · Paris, Franceno status→Not yet recruiting
    • Chu Rouen · Rouen, Franceno status→Not yet recruiting
    Contact Study contact now listed: added c•••@chu-montpellier.fr · •••4853. See the current contact
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • CHRU Lille · Lille, FranceContact added d•••@chu-lille.frContact added (no phone or email listed)
    • Montpellier University Hospital · Montpellier, FranceContact added (no phone or email listed)Contact added c•••@inserm.fr · •••4853
    • APHP Necker · Paris, FranceContact added y•••@me.comContact added (no phone or email listed)
    • Chu Rouen · Rouen, FranceContact added o•••@chu-rouen.fr
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07493395
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Jun 11, 2026
Primary completion
Jun 11, 2028 (estimated)
Completion
Jun 11, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Charlotte KAAN
Contact
c-kaan@chu-montpellier.fr
04 67 33 48 53 ext. 33
Christian Jorgensen, PUPH
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion